Arcutis Biotherapeutics (ARQT) announced the appointment of Todd Edwards as Chief Commercial Officer, CCO, effective immediately. Edwards brings to Arcutis over 25 years of sales, market access, marketing, and general management experience from leading companies in dermatology and immunology. Edwards joins Arcutis from Incyte (INCY), where he was group vice president and business unit head for their immunology business. The Company also announced that Ayisha Jeter, Vice President of Market Access, and interim CCO prior to this announcement, has been promoted to Senior Vice President, Marketing and Market Access, and will assume leadership of all marketing and market access at the Company.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ARQT:
- New Campaign from Arcutis Aims to Educate, Raise Awareness, and Provide Encouragement for Those Living with Seborrheic Dermatitis
- Arcutis Announces Positive Results from INTEGUMENT-PED Pivotal Phase 3 Trial of Roflumilast Cream 0.05% for the Treatment of Atopic Dermatitis in Children Ages 2 to 5
- Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Arcutis announces submission of sNDA to FDA for roflumilast cream 0.15%
- Arcutis Biotherapeutics’ roflumilast cream shows efficacy in atopic dermatitis
Questions or Comments about the article? Write to editor@tipranks.com